Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Thymosin Beta-4: Evidence Summary
Evidence summary for Thymosin Beta-4 across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Thymosin Beta-4 overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Corneal healing | Tier B | 2 | FDA-approved trials for neurotrophic keratitis show significant corneal repair |
| Wound healing | Tier C | 3 | Accelerates dermal and corneal wound healing in multiple small trials |
| Cardiac repair | Tier D | 1 | Preclinical data shows cardiomyocyte survival post-MI; human trials limited |
References (6)
- Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. — Bock-Marquette I, Maar K, Maar S, Lippai B, Faskerti G, et al. . International immunopharmacology (2023) PMID: 36709593
- Thymosin β4: A Multi-Faceted Tissue Repair Stimulating Protein in Heart Injury. — Bjørklund G, Dadar M, Aaseth J, Chirumbolo S . Current medicinal chemistry (2020) PMID: 31333080
- Thymosin β4 and Actin: Binding Modes, Biological Functions and Clinical Applications. — Ying Y, Lin C, Tao N, Hoffman RD, Shi D, et al. . Current protein & peptide science (2023) PMID: 36464872
- Thymosin β4 and the vasculature: multiple roles in development, repair and protection against disease. — Dubé KN, Smart N . Expert opinion on biological therapy (2018) PMID: 30063849
- Thymosin β4 and the anti-fibrotic switch. — Kleinman HK, Kulik V, Goldstein AL . International immunopharmacology (2023) PMID: 36580759
- Thymosin β4 Deficiency Exacerbates Renal and Cardiac Injury in Angiotensin-II-Induced Hypertension. — Kumar N, Liao TD, Romero CA, Maheshwari M, Peterson EL, et al. . Hypertension (Dallas, Tex. : 1979) (2018) PMID: 29632102